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activation and inactivation-versus-voltage relations were not changed by the muta-
tion alone or in coexpression with the WT. The time constants of fast recovery 
from inactivation and of fast and slow deactivation analysed between -120 and 
+20 mV were not changed. The voltage dependent distribution of the current 
amplitudes among fast-, slow- and non-deactivating fractions were not altered. We 
conclude that the apparent decrease in current density may in part explain or may 
have predisposed to the observed LQTS and likely the associated SIDS and TdP.
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Background: One of the main causes of sudden cardiac death is ventri-
cular tachycardia/ventricular ¿ brillation. Several molecular and cellular mecha-
nisms involved remain to be resolved, and appropriate therapies are still needed. 
Interestingly, TRPM4 (Transient Receptor Potential Melastatin 4), a Ca2+ acti-
vated non-selective cation channel is expressed in heart. After activation, this 
protein can decrease the driving force for Ca2+ entry by promoting the mem-
brane depolarization due to massive Na+ entry (Launay et al., 2002). Recently, a 
gain of function mutation in TRPM4 was indirectly implicated to human cardiac 
trouble rhythm disease (Kruse et al, 2009; Liu et al, 2010). However, the phy-
siological role of TRPM4 in the heart is unclear, in particular in rhythm control. 
So we designed this study to determine the role of TRPM4 in heart biology.
Method and results: We used a mouse model with TRPM4 gene invalida-
tion (Trpm4-/-). Echocardiographic analysis showed that Trpm4-/- mice exhibit 
left ventricle hypertrophy and dilation. Electrophysiologic explorations including 
telemetry electrocardiogram in vigil mice and intracardiac exploration by cathe-
terism in vivo demonstrated that Trpm4-/- mice have no alteration of heart rate 
but a lengthened PR and QT intervals and QRS duration associated to sino-atrial 
node pause, atrio-ventricular blocks, atrial ¿ brillation and ventricular extrasys-
toles. Using immunoÀ uorescence on frozen cryostat sections, qPCR and cellular 
electrophysiology, we determined that hypertrophy and conduction disorders are 
not a consequence of ¿ brosis, cardiomyocyte size and connexins Cx40, Cx43 
and Cx45 expression modi¿ cations between Trpm4+/+ and Trpm4-/- mice.
Conclusion: Taken together, all these data suggest that TRPM4 invalidation 
is associated with pathophysiological phenotype characterized by hypertrophy, 
arrhythmias and conduction disorders.
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Every year thousands people are victims of sudden cardiac death, usually fol-
lowing ventricular ¿ brillation. In most patients, the cause is an identi¿ able arrhyth-
mogenic cardiomyopathy, but in 5-10% of cases heart is healthy. Some electrical 
disorders virtually arrhythmogenic have been identi¿ ed, like ShortQT recently 
discovered and classi¿ ed as rare genetic channelopathy. Among all patients 
with shortQT, there has been found an associated genetic mutation in only few. 
Hence the cause of shortQT syndrome can also be one or more unknown muta-
tions or secondary of other pathologies. We have identi¿ ed a family with Short 
QT syndrome related to systemic carnitine de¿ ciency caused by membrane car-
nitine transporter mutation. We studied the effect of carnitine and its derivatives 
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Introduction:  Isolated cardiac conduction block is a relatively common 
condition in the young and the elderly populations. Genetic predisposing 
factors have long been suspected because of numerous familial case reports. 
Deciphering genetic predisposing factors of conduction blocks may give a hint 
at stratifying conduction block carriers in a more ef¿ cient way.
Methods and Results: One Lebanese family (L1) and 2 French fami-
lies (F1 and F2) with autosomal dominant isolated cardiac conduction blocks 
were used for linkage analysis. In these 3 families, affected individuals had 
right bundle branch block, left anterior or posterior hemiblock, AV block 
either alone or in combination but no left bundle branch blocks. A maximum 
combined multipoint lod score of 10.5 was obtained on a genomic interval 
including more than 300 genes. After screening 12 genes of this interval for 
mutation, we found a heterozygous missense mutation of the TRPM4 gene 
in each family: p.Arg164Trp (F1), p.Ala432Thr (L1) and p.Gly844Asp (F2). 
These missense mutations change a conserved residue and were not observed 
in more than 300 chromosomal controls. This gene encodes the TRPM4 
channel, a calcium-activated non-selective cation (CAN) channel of the tran-
sient receptor potential melastatin (TRPM) ion channel family.
Furthermore, we showed by immunohistochemistry that wild-type TRPM4 
channel signal level is higher in bovine atrial cardiomyocytes than in common 
ventricular cells but is highest in Purkinje ¿ bers. Small bundles of highly TRPM4 
positive cells were found in the subendocardium and in rare intramural bundles.
Conclusion: The TRPM4 gene is a causative gene in isolated cardiac conduc-
tion disease and TRPM4 channel is highly expressed in cardiac Purkinje ¿ bers.
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A mutation of hERG (R148W) at heterozygous state was discovered in 
two newborns who died from SIDS, one with prolonged QTc and Torsade de 
Pointes (TdP); and in an adult man with QTc>500 ms, atrio-ventricular block and 
TdP. The electrophysiological properties of this N-terminal hERG mutant were 
explored in Xenopus oocytes injected with either 54 ng of WT/hERG RNA or 
54 ng of R148W/hERG or a mixture of half of each. R148W alone produced a 
current similar to the WT (369±76 nA (mean±sem), n=13 versus 342±55 nA in 
WT, n=13), while the coexpression of 1/2 WT + 1/2 R148W lowered the current 
by 29% versus WT (243±35 nA, n=13, p<0.05). Parameters of the steady-state 
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Background: Patients with mental illness have a cardiovascular mortality 
substantially higher than in the genreral population. This excess of mortality is 
partly related to the risk of sudden death associated with prolongation of QT 
interval and torsades de pointe.
Objectives: We conducted a prospective study to appreciate the proportion 
of QT interval prolongation with psychotropic drugs, and to assess the inte-
rest of the electrogram during introduction or increase of psychotropic drug.
Methods: We enrolled 50 subjects (37 men and 13 women, mean age 44 
+/- 14 years) without any cardiological story. They were hospitalised in a psy-
chiatric ward for more than 2 weeks to bene¿ t from introduction or increase 
of psychotropic drug with a QT prolongation effect. Patients were divided in 
two groups. The ¿ rst one comprised 27 subjects taking no drug at strat. The 
second group comprised 23 subjects already treated with psychotropic drugs. 
ECGs were performed at strat and at discharge; QT interval was corrected for 
heart rate according to Bazett’s formula.
Results: A signi¿ cant prolongation of QTc is found on the entire popula-
tion (11.3 +/- 17 ms, p=0.012). The lengthening of QTc was limit of signi-
¿ cance in the ¿ rst group (14 +/- 20 ms, p=0.053), but not signi¿ cant in the 
second group (7+/- 13 ms, p=0.085). Four patients (8%) developed patholo-
gical QTc interval ( QTc > 450 ms for men, QTc > 470 ms for women), but 
all were under 500 ms.
Conclusion: Due to the multiple drugs prescription particularly in psychia-
tric ward, it seems legitimate to make an ECG with QTc monitoring for all 
patients.  
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Background: TRPM4 is a non-selective monovalent cation channel widely 
expressed in different tissues. In the heart, its functional expression was 
reported in sino-atrial node and atrium. However, demonstration of its impli-
cation in the action potential was never showed because of the lack of speci¿ c 
pharmacological tools. Recently, we observed that 9-phenanthrol, a benzo[c]
quinolizinium derivative, speci¿ cally blocks TRPM4 (Grand et al. 2008, Br. 
J. Pharmacol.). Here we investigated the effect of this molecule on the mouse 
atrial action potential (AP).
Methods: Transmembrane potential was recorded using the conventional 
intracellular microelectrode technique after isolation of right atrium from 
Trpm4+/+ or Trpm4-/- mice. The preparation was continuously superfused with 
a physiological solution and electrical stimulation at a pacing rate of 5 Hz was 
applied to induce AP.
Results: Atrial cardiomyocytes from Trpm4-/- mice showed similar 
resting membrane potential, and AP amplitude but a reduction close to 
20% in AP duration (APD) at 50, 70 and 90% of repolarization, when com-
pared to Trpm4+/+ AP. 9-phenanthrol was added in the superfused solution 
during continuous action potential recordings. It signi¿ cantly and reversibly 
decreased the AP duration in atrium from Trpm4+/+ mice, with a concentra-
tion for half-maximal reduction (EC50) at 21 10-3 M. This EC50 is similar 
to that reported for the inhibitory effect of 9-phenanthrol on over-expressed 
TRPM4 current in HEK-293 cells (Grand et al. 2008, Br. J. Pharmacol.). The 
9- phenanthrol did not exert any signi¿ cant effect on other AP parameters. 
Moreover, 9- phenanthrol effect on AP was almost abolished in Trpm4-/-. Only 
a tiny effect was detected at the highest concentration (10-4 M).
Conclusion: Our results showed that TRPM4 is implicated in the wave-
form of the atrial action potential.
on hERG, IKS, IK1 and ICaL channels, since they are the channels involved in 
genetic ShortQT. HEK293 cells stably expressing hERG, IK1 and ICaL chan-
nels were studied in patch clamp in whole-cell con¿ guration, while IKS channel 
in perforated-patch con¿ guration. Different derivatives (medium- or long-chain-
acyl-carnitine (LCAC)) and concentrations (between 1 up to 30 M) were used 
for each channel. Carnitine derivatives had no effects on IK1 and IKS, no matter 
the concentration. For hERG channel only LCAC extracellularly applied modulate 
hERG current. They induce an increase of current amplitude and a dose-dependent 
speeding of deactivation kinetic. Modelisation shows that the effect is a longer 
action potential. So potassium channels are not resposable of ShortQT observed. 
We then observed ICaL, since it has an important role in action potential plateau 
phase. ICaL is modulated by C16-CAR shortening the action potential that could 
explain Short QT observed. But we also observed the same effect with relative 
fatty acid, C16, meaning that ICaL is not responsable of ShortQT. Thus we have 
to search farther ShortQT causes linked to carnitine de¿ ciency.
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Introduction: Early repolarization syndrome (ERS) has been recently linked to 
idiopathic ventricular ¿ brillation. Identi¿ cation of a mutation in KCNJ8 gene sug-
gests a genetic substrate underlying in this syndrome. Familial form of the disease 
has been identi¿ ed but the variability of the ECG pattern can lead to an underes-
timation of the syndrome within the families. The aim of the present study was to 
evaluate the ability of the Valsalva maneuver (VM) to unmask the ERS.
Methods: We have screened relatives of 2 large families affected by a 
familial form ERS leading to the occurrence of 4 sudden cardiac death (SCD) 
in both families. Patients were considered to be affected by ER in the presence 
of a distinct J-wave, de¿ ned as a positive deÀ ection on the S wave in two 
consecutive leads and at least a 1 mm amplitude above baseline.
Results: In the ¿ rst family, familial screening identi¿ ed 4 SCD and 22 ER 
out of 89 available ECG (prevalence 26%). In the second family, 4 SCD 
occurred and 20 other patients out of 30 had an ER pattern (prevalence 58%). 
In those families, ER is transmitted with an autosomal dominant trait.
VM was performed for 72 relatives. Heart rate decreased from 3,05 beat/
min (-22; +11 bpm) during the test. VM unmasked the ER in 6 obligate car-
riers and in 9 other unaffected patients leading to the diagnosis in 15/53 (28%) 
of family members with a normal resting ECG. VM increased ER amplitude 
for more than one mm in 74% (14/19) of affected patients.
Conclusion: Malignant forms of ERS can be transmitted as an auto-
somal dominant trait in large families. Valsalva maneuver could be helpful to 
improve or reveal ER for familial screening of relatives. Prognosis value of 
this test have to be evaluated.
Family 1
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